Mga Batayang Estadistika
| LEI | 5493006HO04GB8AQ2V43 |
| CIK | 1792267 |
SEC Filings
All companies that sell securities in the United States must register with the Securities and Exchange Commission (SEC) and file reports on a regular basis.
These reports include company annual reports (10K, 10Q), news updates (8K), investor presentations (found in 8Ks), insider trades (form 4), ownership reports (13D, and 13G), and reports related to the specific securities sold, such as registration statements and prospectus. This page shows recent SEC filings related to Burning Rock Biotech Limited - Depositary Receipt (Common Stock)
SEC Filings (Chronological Order)
Halaman ini menyediakan daftar lengkap dan kronologis dari Pengajuan SEC, tidak termasuk pengajuan kepemilikan yang kami sediakan di tempat lain.
| June 6, 2025 |
Form 6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of June 2025 Commission File Number: 001-39316 BURNING ROCK BIOTECH LIMITED (Registrant’s Name) No.5 Xingdao Ring Road North, International Bio Island Guangzhou, Guangdong People’s Republ |
|
| June 6, 2025 |
Burning Rock Reports First Quarter 2025 Financial Results Exhibit 99.1 Burning Rock Reports First Quarter 2025 Financial Results GUANGZHOU, China, June 6, 2025—Burning Rock Biotech Limited (NASDAQ: BNR, the “Company” or “Burning Rock”), a company focused on the application of next generation sequencing (NGS) technology in the field of precision oncology, today reported financial results for the three months ended March 31, 2025. Recent Business Updates • |
|
| April 29, 2025 |
EX-12.1 Exhibit 12.1 CERTIFICATION OF PRINCIPAL EXECUTIVE OFFICER PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002 I, Yusheng Han, certify that: 1. I have reviewed this annual report on Form 20-F, as amended, of Burning Rock Biotech Limited; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the |
|
| April 29, 2025 |
Supplementary Agreement to Equity Pledge Contract (III) Exhibit 4.16 Supplementary Agreement to Equity Pledge Contract (III) The Supplementary Agreement to Equity Pledge Contract (III) (the “Supplementary Agreement”) is made and entered into by the following parties on 10 May 2024 in Beijing, the People’s Republic of China (the “PRC”, which for the purpose of the Supplementary Agreement excludes the territories of Hong Kong, Macao, and Taiwan Province) |
|
| April 29, 2025 |
Supplementary Agreement to Exclusive Business Cooperation Agreement Exhibit 4.14 Supplementary Agreement to Exclusive Business Cooperation Agreement The Exclusive Business Cooperation Agreement (the “Agreement”) is made an entered into on 10 May 2024, in Beijing, the People’s Republic of China (the “PRC”, which for the purpose of the Agreement excludes the territories of Hong Kong, Macao, and Taiwan Province), by and between the parties hereto. Party A: Beijing Bu |
|
| April 29, 2025 |
Exhibit 15.2 Suit 509, Tower A, Corporate Square, 35 Financial Street, Xicheng District, Beijing, China Tel: (86-10) 5776 3888 Fax: (86-10) 5776 3777 Date: April 29, 2025 To: Burning Rock Biotech Limited (the “Company”) No. 5, Xingdao Ring Road North, International Bio Island, Guangzhou, 510005 The People’s Republic of China Dear Sirs/Madams, We hereby consent to the use of our name under the head |
|
| April 29, 2025 |
Exhibit 4.18 Spouse’s Consent To: Guangzhou Burning Rock Biotech Co., Ltd Whereas: 1. I, [Name of Spouse] (ID card No.: ●), is the spouse of natural person [Name of Shareholder] (ID card No.: ● [Name of Shareholder] holds [ ]% equity of Burning Rock (Beijing) Biotechnology Co., Ltd (the “Underlying Equity”). 2. In connection with the above-mentioned underlying equity held by [Name of Shareholder], |
|
| April 29, 2025 |
Consent of Independent Registered Public Accounting Firm Exhibit 15.1 Consent of Independent Registered Public Accounting Firm We consent to the incorporation by reference in the following Registration Statements: (1) Registration Statement (Form S-8 No. 333-251191) pertaining to the Pre-IPO Share Incentive Plan, 2020 Equity Incentive Plan, Management Share Incentive Plan, Employee Share Incentive Plan No.1 and Employee Share Incentive Plan No. 2 of Bur |
|
| April 29, 2025 |
Supplementary Agreement to Power of Attorney Exhibit 4.17 Supplementary Agreement to Power of Attorney The Supplementary Agreement to Power of Attorney (the “Supplementary Agreement”) is made and entered into on 10 May 2024 in Beijing, the People’s Republic of China (the “PRC”, which for the purpose of the Agreement excludes the territories of Hong Kong, Macao, and Taiwan Province), by and between the parties hereto: Party A: Beijing Burning |
|
| April 29, 2025 |
EX-13.1 Exhibit 13.1 CERTIFICATION BY THE PRINCIPAL EXECUTIVE OFFICER PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002 In connection with the Annual Report of Burning Rock Biotech Limited (the “Company”) on Form 20-F for the fiscal year ended December 31, 2024 as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I, Yusheng Han, Chairman of the Board of D |
|
| April 29, 2025 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 20-F (Mark One) ☐ REGISTRATION STATEMENT PURSUANT TO SECTION 12(b) OR (g) OF THE SECURITIES ACT OF 1934 OR ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECUR |
|
| April 29, 2025 |
Supplementary Agreement to Exclusive Call Option Contract (III) Exhibit 4.15 Supplementary Agreement to Exclusive Call Option Contract (III) The Supplementary Agreement to the Exclusive Call Option Contract (III) (the “Supplementary Agreement”) is made and entered into by and among the following parties on 10 May 2024 in Beijing, the People’s Republic of China (the “PRC”, excluding, for the purpose of the Supplementary Agreement, the Hong Kong, the Macao and T |
|
| April 29, 2025 |
Exhibit 4.19 Voting Proxy Agreement This Voting Proxy Agreement (this “Agreement”) is entered into by and between the parties as of May 10, 2024 in Guangzhou, People’s Republic of China (“PRC”, for the purpose of this Agreement, PRC shall not include Hong Kong, Macau and Taiwan): Party A: Guangzhou Burning Rock Biotechnology Co., Ltd. Registered Address: [***] Party B: Burning Rock Biotech Limited |
|
| April 29, 2025 |
EX-13.2 Exhibit 13.2 CERTIFICATION BY THE PRINCIPAL FINANCIAL OFFICER PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002 In connection with the Annual Report of Burning Rock Biotech Limited (the “Company”) on Form 20-F for the fiscal year ended December 31, 2024 as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I, Xiaozhi Hu, Senior Director of Finance |
|
| April 29, 2025 |
Exhibit 11.2 AMENDED AND RESTATED STATEMENT OF POLICIES GOVERNING MATERIAL NON-PUBLIC INFORMATION AND THE PREVENTION OF INSIDER TRADING OF BURNING ROCK BIOTECH LIMITED (Adopted by the Board of Directors of Burning Rock Biotech Limited on April 28, 2025, effective immediately) This Amended and Restated Statement of Policies Governing Material Non-Public Information and the Prevention of Insider Tra |
|
| April 29, 2025 |
EX-12.2 Exhibit 12.2 CERTIFICATION OF PRINCIPAL FINANCIAL OFFICER PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002 I, Xiaozhi Hu, certify that: 1. I have reviewed this annual report on Form 20-F, as amended, of Burning Rock Biotech Limited; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the |
|
| March 25, 2025 |
Burning Rock Reports Unaudited Fourth Quarter and Full Year 2024 Financial Results Exhibit 99.1 Burning Rock Reports Unaudited Fourth Quarter and Full Year 2024 Financial Results GUANGZHOU, China, March 25, 2025—Burning Rock Biotech Limited (NASDAQ: BNR, the “Company” or “Burning Rock”), a company focused on the application of next generation sequencing (NGS) technology in the field of precision oncology, today reported unaudited financial results for the three months and the ye |
|
| March 25, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of March 2025 Commission File Number: 001-39316 BURNING ROCK BIOTECH LIMITED (Registrant’s Name) No.5 Xingdao Ring Road North, International Bio Island Guangzhou, Guangdong People’s Republic of Ch |
|
| December 31, 2024 |
Form 6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of December 2024 Commission File Number: 001-39316 BURNING ROCK BIOTECH LIMITED (Registrant’s Name) No.5 Xingdao Ring Road North, International Bio Island Guangzhou, Guangdong People’s Re |
|
| December 31, 2024 |
Burning Rock Announces Results of 2024 Annual General Meeting Exhibit 99.1 Burning Rock Announces Results of 2024 Annual General Meeting GUANGZHOU, China, December 31, 2024—Burning Rock Biotech Limited (NASDAQ: BNR, the “Company” or “Burning Rock”), a company focusing on the application of next generation sequencing (NGS) technology in the field of precision oncology, today announced that all shareholder resolutions proposed at the Company’s 2024 annual gene |
|
| December 4, 2024 |
Burning Rock Reports Third Quarter 2024 Financial Results Exhibit 99.1 Burning Rock Reports Third Quarter 2024 Financial Results GUANGZHOU, China, December 4, 2024—Burning Rock Biotech Limited (NASDAQ: BNR, the “Company” or “Burning Rock”), a company focused on the application of next generation sequencing (NGS) technology in the field of precision oncology, today reported financial results for the three months ended September 30, 2024. Recent Business U |
|
| December 4, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of December 2024 Commission File Number: 001-39316 BURNING ROCK BIOTECH LIMITED (Registrant’s Name) No.5 Xingdao Ring Road North, International Bio Island Guangzhou, Guangdong People’s Republic of |
|
| December 3, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of December 2024 Commission File Number: 001-39316 BURNING ROCK BIOTECH LIMITED (Registrant’s Name) No.5 Xingdao Ring Road North, International Bio Island Guangzhou, Guangdong People’s Republic of |
|
| December 3, 2024 |
Burning Rock Announces 2024 Annual General Meeting to be Held on December 31, 2024 Exhibit 99.1 Burning Rock Announces 2024 Annual General Meeting to be Held on December 31, 2024 GUANGZHOU, China, December 3, 2024—Burning Rock Biotech Limited (NASDAQ: BNR, the “Company” or “Burning Rock”), a company focusing on the application of next generation sequencing (NGS) technology in the field of precision oncology, today announced that it will hold its annual general meeting (“AGM”) on |
|
| December 3, 2024 |
Exhibit 99.3 BURNING ROCK BIOTECH LIMITED FORM OF PROXY FOR THE ANNUAL GENERAL MEETING TO BE HELD ON DECEMBER 31, 2024 (OR ANY ADJOURNMENTS OR POSTPONEMENTS THEREOF) Introduction This Form of Proxy is furnished in connection with the solicitation by the Board of Directors of Burning Rock Biotech Limited, an exempted company incorporated in the Cayman Islands with limited liability (the “Company”), |
|
| December 3, 2024 |
Exhibit 99.4 Annual General Meeting The Voting Instructions must be signed, completed and received at the indicated address prior to 10:00 A.M. (New York City time) on December 20, 2024 for action to be taken. 2024 VOTING INSTRUCTIONS AMERICAN DEPOSITARY SHARES Burning Rock Biotech Limited (the “Company”) ADS CUSIP No.: 12233L206.* ADS Record Date:December 4, 2024 Meeting Specifics:Annual General |
|
| December 3, 2024 |
BURNING ROCK BIOTECH LIMITED NOTICE OF ANNUAL GENERAL MEETING TO BE HELD ON DECEMBER 31, 2024 Exhibit 99.2 BURNING ROCK BIOTECH LIMITED NOTICE OF ANNUAL GENERAL MEETING TO BE HELD ON DECEMBER 31, 2024 NOTICE IS HEREBY GIVEN that the annual general meeting (the “AGM”) of Burning Rock Biotech Limited (NASDAQ: BNR, the “Company” or “Burning Rock”) will be held on December 31, 2024 at 10:00 a.m. (local time) at the Company’s Shanghai office at 6/F, Building 10C, Pujiang Smart Plaza, No. 2168 C |
|
| November 26, 2024 |
EX-12.2 Exhibit 12.2 CERTIFICATION OF PRINCIPAL FINANCIAL OFFICER PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002 I, Xiaozhi Hu, certify that: 1. I have reviewed this annual report on Form 20-F, as amended, of Burning Rock Biotech Limited; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the |
|
| November 26, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 20-F (Amendment No. 1) (Mark One) ☐ REGISTRATION STATEMENT PURSUANT TO SECTION 12(b) OR (g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF |
|
| November 26, 2024 |
CORRESP November 26, 2024 VIA EDGAR Christie Wong Li Xiao Division of Corporation Finance Office of Industrial Applications and Services U. |
|
| November 26, 2024 |
EX-12.1 Exhibit 12.1 CERTIFICATION OF PRINCIPAL EXECUTIVE OFFICER PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002 I, Yusheng Han, certify that: 1. I have reviewed this annual report on Form 20-F, as amended, of Burning Rock Biotech Limited; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the |
|
| November 14, 2024 |
SC 13G/A 1 bnra2111424.htm KYNAM CAPITAL MANAGEMENT, LP UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 2)* Burning Rock Biotech Limited (Name of Issuer) American Depository Shares ("ADSs") of the Issuer, each ADS representing one Class A Ordinary Share, par value $0.0002 per share (Title of Class of Secu |
|
| September 27, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of September 2024 Commission File Number: 001-39316 BURNING ROCK BIOTECH LIMITED (Registrant’s Name) No.5 Xingdao Ring Road North, International Bio Island Guangzhou, Guangdong People’s Republic o |
|
| September 27, 2024 |
Burning Rock Announces Changes to Management and Board of Directors Exhibit 99.1 Burning Rock Announces Changes to Management and Board of Directors GUANGZHOU, China, September 27, 2024 — Burning Rock Biotech Limited (NASDAQ: BNR) (the “Company” or “Burning Rock”), a company focused on the application of next generation sequencing (NGS) technology in the field of precision oncology, today announced the resignation of Mr. Leo Li as a director from the Company’s boa |
|
| September 20, 2024 |
Form 6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of September 2024 Commission File Number: 001-39316 BURNING ROCK BIOTECH LIMITED (Registrant’s Name) No.5 Xingdao Ring Road North, International Bio Island Guangzhou, Guangdong People’s R |
|
| September 18, 2024 |
Filed pursuant to Rule 424(b)(3) Registration Statement on Form F-6 Registration No. |
|
| September 6, 2024 |
Form 6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of September 2024 Commission File Number: 001-39316 BURNING ROCK BIOTECH LIMITED (Registrant’s Name) No.5 Xingdao Ring Road North, International Bio Island Guangzhou, Guangdong People’s R |
|
| August 23, 2024 |
Form 6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of August 2024 Commission File Number: 001-39316 BURNING ROCK BIOTECH LIMITED (Registrant’s Name) No.5 Xingdao Ring Road North, International Bio Island Guangzhou, Guangdong People’s Repu |
|
| August 23, 2024 |
Burning Rock Reports Second Quarter 2024 Financial Results Exhibit 99.1 Burning Rock Reports Second Quarter 2024 Financial Results GUANGZHOU, China, August 23, 2024—Burning Rock Biotech Limited (NASDAQ: BNR and LSE: BNR, the “Company” or “Burning Rock”), a company focused on the application of next generation sequencing (NGS) technology in the field of precision oncology, today reported financial results for the three months ended June 30, 2024. Recent Bu |
|
| August 19, 2024 |
Form 6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of August 2024 Commission File Number: 001-39316 BURNING ROCK BIOTECH LIMITED (Registrant’s Name) No.5 Xingdao Ring Road North, International Bio Island Guangzhou, Guangdong People’s Repu |
|
| August 19, 2024 |
Exhibit 99.1 BURNING ROCK BIOTECH LIMITED August 19, 2024 Burning Rock Biotech Limited Announces Expected Delisting of American Depositary Shares Burning Rock Biotech Limited (the “Company” or “Burning Rock”) announces that, on August 19, 2024, it intends to submit requests (a) to the London Stock Exchange (the “LSE”), to cancel the admission to trading on the Main Market of its American Depositar |
|
| June 3, 2024 |
Form 6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of June 2024 Commission File Number: 001-39316 BURNING ROCK BIOTECH LIMITED (Registrant’s Name) No.5 Xingdao Ring Road North, International Bio Island Guangzhou, Guangdong People’s Republ |
|
| June 3, 2024 |
Burning Rock Regains Compliance with NASDAQ Minimum Bid Price Requirement Exhibit 99.1 Burning Rock Regains Compliance with NASDAQ Minimum Bid Price Requirement GUANGZHOU, China, June 3, 2024—Burning Rock Biotech Limited (NASDAQ: BNR and LSE: BNR, the “Company” or “Burning Rock”), a company focused on the application of next generation sequencing (NGS) technology in the field of precision oncology, today announced that it has received a notification letter from the staf |
|
| May 29, 2024 |
Form 6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of May 2024 Commission File Number: 001-39316 BURNING ROCK BIOTECH LIMITED (Registrant’s Name) No.5 Xingdao Ring Road North, International Bio Island Guangzhou, Guangdong People’s Republi |
|
| May 29, 2024 |
Burning Rock Reports First Quarter 2024 Financial Results Exhibit 99.1 Burning Rock Reports First Quarter 2024 Financial Results GUANGZHOU, China, May 29, 2024—Burning Rock Biotech Limited (NASDAQ: BNR and LSE: BNR, the “Company” or “Burning Rock”), a company focused on the application of next generation sequencing (NGS) technology in the field of precision oncology, today reported financial results for the three months ended March 31, 2024. Recent Busin |
|
| May 14, 2024 |
Burning Rock Announces ADS Ratio Change to Be Effective on May 15, 2024 EX-99.1 Exhibit 99.1 Burning Rock Announces ADS Ratio Change to Be Effective on May 15, 2024 GUANGZHOU, China, May 14, 2024—Burning Rock Biotech Limited (NASDAQ: BNR and LSE: BNR, the “Company” or “Burning Rock”), a company focused on the application of next generation sequencing (NGS) technology in the field of precision oncology, today announced that, as previously announced on April 26, 2024, t |
|
| May 14, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of May 2024 Commission File Number: 001-39316 BURNING ROCK BIOTECH LIMITED (Registrant’s Name) No.5 Xingdao Ring Road North, International Bio Island Guangzhou, Guangdong People’s Republic of Chin |
|
| April 29, 2024 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 20-F (Mark One) ☐ REGISTRATION STATEMENT PURSUANT TO SECTION 12(b) OR (g) OF THE SECURITIES ACT OF 1934 OR ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECUR |
|
| April 29, 2024 |
Exhibit 15.2 Suit 509, Tower A, Corporate Square, 35 Financial Street, Xicheng District, Beijing, China Tel: (86-10) 5776 3888 Fax: (86-10) 5776 3777 Date: April 29, 2023 To: Burning Rock Biotech Limited (the “Company”) No. 5, Xingdao Ring Road North, International Bio Island, Guangzhou, 510005 The People’s Republic of China Dear Sirs/Madams, We hereby consent to the use of our name under the head |
|
| April 29, 2024 |
Consent of Independent Registered Public Accounting Firm Exhibit 15.1 Consent of Independent Registered Public Accounting Firm We consent to the incorporation by reference in the following Registration Statements: (1) Registration Statement (Form S-8 No. 333-251191) pertaining to the Pre-IPO Share Incentive Plan, 2020 Equity Incentive Plan, Management Share Incentive Plan, Employee Share Incentive Plan No. 1 and Employee Share Incentive Plan No. 2 of Bu |
|
| April 29, 2024 |
EX-13.2 Exhibit 13.2 CERTIFICATION BY THE PRINCIPAL FINANCIAL OFFICER PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002 In connection with the Annual Report of Burning Rock Biotech Limited (the “Company”) on Form 20-F for the fiscal year ended December 31, 2023 as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I, Leo Li, Chief Financial Officer of the |
|
| April 29, 2024 |
Exhibit 11.2 AMENDED AND RESTATED STATEMENT OF POLICIES GOVERNING MATERIAL NON-PUBLIC INFORMATION AND THE PREVENTION OF INSIDER TRADING OF BURNING ROCK BIOTECH LIMITED (Adopted by the Board of Directors of Burning Rock Biotech Limited on November 21, 2023, effective immediately) This Amended and Restated Statement of Policies Governing Material Non-Public Information and the Prevention of Insider |
|
| April 29, 2024 |
EX-12.1 Exhibit 12.1 CERTIFICATION OF PRINCIPAL EXECUTIVE OFFICER PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002 I, Yusheng Han, certify that: 1. I have reviewed this annual report on Form 20-F of Burning Rock Biotech Limited; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements m |
|
| April 29, 2024 |
EX-12.2 Exhibit 12.2 CERTIFICATION OF PRINCIPAL FINANCIAL OFFICER PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002 I, Leo Li, certify that: 1. I have reviewed this annual report on Form 20-F of Burning Rock Biotech Limited; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, |
|
| April 29, 2024 |
BURNING ROCK BIOTECH LIMITED POLICY FOR THE RECOVERY OF ERRONEOUSLY AWARDED COMPENSATION Exhibit 97.1 BURNING ROCK BIOTECH LIMITED POLICY FOR THE RECOVERY OF ERRONEOUSLY AWARDED COMPENSATION 1. Purpose. The purpose of this Policy is to describe the circumstances in which Executive Officers will be required to repay or return Erroneously Awarded Compensation to the Company in accordance with the Clawback Rules. Each Executive Officer shall be required to sign and return to the Company |
|
| April 29, 2024 |
EX-13.1 Exhibit 13.1 CERTIFICATION BY THE PRINCIPAL EXECUTIVE OFFICER PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002 In connection with the Annual Report of Burning Rock Biotech Limited (the “Company”) on Form 20-F for the fiscal year ended December 31, 2023 as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I, Yusheng Han, Chairman of the Board of D |
|
| April 26, 2024 |
Burning Rock Announces ADS Ratio Change Exhibit 99.1 Burning Rock Announces ADS Ratio Change GUANGZHOU, China, April 26, 2024—Burning Rock Biotech Limited (NASDAQ: BNR and LSE: BNR, the “Company” or “Burning Rock”), a company focused on the application of next generation sequencing (NGS) technology in the field of precision oncology, today announced that it will change the ratio of its American depositary shares (the “ADSs”) to Class A |
|
| April 26, 2024 |
Exhibit (a)(i) AMENDMENT NO. 1 TO DEPOSIT AGREEMENT by and among BURNING ROCK BIOTECH LIMITED AND CITIBANK, N.A., as Depositary, AND ALL HOLDERS AND BENEFICIAL OWNERS OF AMERICAN DEPOSITARY SHARES ISSUED HEREUNDER Dated as of [l], 2024 Table of Contents Page ARTICLE I DEFINITIONS 1 Section 1.1 Definitions. 1 Section 1.2 Effective Date. 1 ARTICLE II AMENDMENTS TO DEPOSIT AGREEMENT 2 Section 2.1 Dep |
|
| April 26, 2024 |
As filed with the Securities and Exchange Commission on April 26, 2024 Registration No. |
|
| April 26, 2024 |
Form 6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of April 2024 Commission File Number: 001-39316 BURNING ROCK BIOTECH LIMITED (Registrant’s Name) No.5 Xingdao Ring Road North, International Bio Island Guangzhou, Guangdong People’s Repub |
|
| March 28, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of March 2024 Commission File Number: 001-39316 BURNING ROCK BIOTECH LIMITED (Registrant’s Name) No.5 Xingdao Ring Road North, International Bio Island Guangzhou, Guangdong People’s Republic of Ch |
|
| March 28, 2024 |
Burning Rock Reports Fourth Quarter and Full Year 2023 Financial Results Exhibit 99.1 Burning Rock Reports Fourth Quarter and Full Year 2023 Financial Results GUANGZHOU, China, March 29, 2024—Burning Rock Biotech Limited (NASDAQ: BNR and LSE: BNR, the “Company” or “Burning Rock”), a company focused on the application of next generation sequencing (NGS) technology in the field of precision oncology, today reported financial results for the three months and the year ende |
|
| February 14, 2024 |
SC 13G/A 1 bnra121424.htm KYNAM CAPITAL MANAGEMENT, LP UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1)* Burning Rock Biotech Limited (Name of Issuer) American Depository Shares ("ADSs") of the Issuer, each ADS representing one Class A Ordinary Share, par value $0.0002 per share (Title of Class of Secur |
|
| February 14, 2024 |
SC 13G/A 1 d758491dsc13ga.htm SC 13G/A SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G (Rule 13d-102) Information to be Included in Statements Filed Pursuant to § 240.13d-1(b), (c) and (d) and Amendments Thereto Filed Pursuant to § 240.13d-2 Under the Securities Exchange Act of 1934 (Amendment No. 2)* Burning Rock Biotech Limited (Name of Issuer) Class A Ordinary Shares, par |
|
| February 13, 2024 |
SC 13G 1 ea193271-13glavbio5burning.htm SCHEDULE 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* Burning Rock Biotech Limited (Name of Issuer) Class A Ordinary Shares, par value $0.0002 per share (Title of Class of Securities) G17173 108** (CUSIP Number) December 31, 2023 (Date of Event Which Require |
|
| February 13, 2024 |
EX-99.1 2 ea193271ex99-1burning.htm AGREEMENT OF JOINT FILING Exhibit 99.1 AGREEMENT OF JOINT FILING The undersigned hereby agree that a single Schedule 13G (or any amendment thereto) relating to the Class A Ordinary Shares of Burning Rock Biotech Limited shall be filed on behalf of each of the undersigned and that this Agreement shall be filed as an exhibit to such Schedule 13G. Dated: February 1 |
|
| February 9, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 2) * Burning Rock Biotech Limited (Name of Issuer) American depositary shares, each representing one Class A ordinary share, par value US$0.0002 per share (Title of Class of Securities) 12233L107 (CUSIP Number) December 31, 2023 (Date of the Event Which Requ |
|
| February 9, 2024 |
Exhibit A Joint Filing Agreement In accordance with Rule 13d-1(k) promulgated under the U. |
|
| January 10, 2024 |
SC 13G 1 bnr11024.htm KYNAM CAPITAL MANAGEMENT, LP UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 Burning Rock Biotech Limited (Name of Issuer) Class A Ordinary Shares (Title of Class of Securities) 12233L107 (CUSIP Number) December 31, 2023 (Date of Event which Requires Filing of this Statement) Check the appropriate |
|
| January 4, 2024 |
Form 6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of January 2024 Commission File Number: 001-39316 BURNING ROCK BIOTECH LIMITED (Registrant’s Name) No.5 Xingdao Ring Road North, International Bio Island Guangzhou, Guangdong People’s Rep |
|
| January 4, 2024 |
Burning Rock Announces Receipt of Notification from NASDAQ Exhibit 99.1 Burning Rock Announces Receipt of Notification from NASDAQ GUANGZHOU, China, January 4, 2024—Burning Rock Biotech Limited (NASDAQ: BNR and LSE: BNR, the “Company” or “Burning Rock”), a company focused on the application of next generation sequencing (NGS) technology in the field of precision oncology, today announced that it has received written notification from the staff of the List |
|
| December 20, 2023 |
Burning Rock Announces Results of 2023 Annual General Meeting EX-99.1 Exhibit 99.1 Burning Rock Announces Results of 2023 Annual General Meeting GUANGZHOU, China, December 20, 2023—Burning Rock Biotech Limited (NASDAQ: BNR and LSE: BNR, the “Company” or “Burning Rock”), a company focusing on the application of next generation sequencing (NGS) technology in the field of precision oncology, today announced that all shareholder resolutions proposed at the Compa |
|
| December 20, 2023 |
Form 6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of December 2023 Commission File Number: 001-39316 BURNING ROCK BIOTECH LIMITED (Registrant’s Name) No.5 Xingdao Ring Road North, International Bio Island Guangzhou, Guangdong People’s Re |
|
| November 30, 2023 |
Form 6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of November 2023 Commission File Number: 001-39316 BURNING ROCK BIOTECH LIMITED (Registrant’s Name) No.5 Xingdao Ring Road North, International Bio Island Guangzhou, Guangdong People’s Re |
|
| November 30, 2023 |
Burning Rock Reports Third Quarter 2023 Financial Results Exhibit 99.1 Burning Rock Reports Third Quarter 2023 Financial Results GUANGZHOU, China, November 30, 2023—Burning Rock Biotech Limited (NASDAQ: BNR and LSE: BNR, the “Company” or “Burning Rock”), a company focused on the application of next generation sequencing (NGS) technology in the field of precision oncology, today reported financial results for the three months ended September 30, 2023. Rec |
|
| November 22, 2023 |
Exhibit 99.3 BURNING ROCK BIOTECH LIMITED FORM OF PROXY FOR THE ANNUAL GENERAL MEETING TO BE HELD ON DECEMBER 20, 2023 (OR ANY ADJOURNMENTS OR POSTPONEMENTS THEREOF) Introduction This Form of Proxy is furnished in connection with the solicitation by the Board of Directors of Burning Rock Biotech Limited, an exempted company incorporated in the Cayman Islands with limited liability (the “Company”), |
|
| November 22, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of November 2023 Commission File Number: 001-39316 BURNING ROCK BIOTECH LIMITED (Registrant’s Name) No.5 Xinghuan Ring Road North, International Bio Island Guangzhou, Guangdong People’s Republic o |
|
| November 22, 2023 |
Burning Rock Announces 2023 Annual General Meeting to be Held on December 20, 2023 Exhibit 99.1 Burning Rock Announces 2023 Annual General Meeting to be Held on December 20, 2023 GUANGZHOU, China, November 22, 2023—Burning Rock Biotech Limited (NASDAQ: BNR and LSE: BNR, the “Company” or “Burning Rock”), a company focusing on the application of next generation sequencing (NGS) technology in the field of precision oncology, today announced that it will hold its annual general meet |
|
| November 22, 2023 |
BURNING ROCK BIOTECH LIMITED NOTICE OF ANNUAL GENERAL MEETING TO BE HELD ON DECEMBER 20, 2023 Exhibit 99.2 BURNING ROCK BIOTECH LIMITED NOTICE OF ANNUAL GENERAL MEETING TO BE HELD ON DECEMBER 20, 2023 NOTICE IS HEREBY GIVEN that the annual general meeting (the “AGM”) of Burning Rock Biotech Limited (NASDAQ: BNR and LSE: BNR, the “Company” or “Burning Rock”) will be held on December 20, 2023 at the Company’s Shanghai office at 6/F, Building 10C, Pujiang Smart Plaza, No. 2168 Chenhang Highwa |
|
| September 5, 2023 |
Burning Rock Reports Second Quarter 2023 Financial Results EX-99.1 Exhibit 99.1 Burning Rock Reports Second Quarter 2023 Financial Results GUANGZHOU, China, August 31, 2023—Burning Rock Biotech Limited (NASDAQ: BNR and LSE: BNR, the “Company” or “Burning Rock”), a company focused on the application of next generation sequencing (NGS) technology in the field of precision oncology, today reported financial results for the three months ended June 30, 2023. R |
|
| September 5, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of September 2023 Commission File Number: 001-39316 BURNING ROCK BIOTECH LIMITED (Registrant’s Name) No.5 Xingdao Ring Road North, International Bio Island Guangzhou, Guangdong People’s Republic o |
|
| August 30, 2023 |
Burning Rock Biotech Limited No. 5, Xingdao Ring Road North International Bio Island Guangzhou 510005 People’s Republic of China August 30, 2023 VIA EDGAR Tyler Howes Jennifer Gowetski Division of Corporation Finance Disclosure Review Program U.S. Securities and Exchange Commission 100 F Street, N.E. Washington, D.C. 20549 Re: Burning Rock Biotech Limited (the “Company”) Form 20-F for the fiscal y |
|
| August 11, 2023 |
Burning Rock Biotech Limited No. 5, Xingdao Ring Road North International Bio Island, Guangzhou, 510005 People’s Republic of China August 11, 2023 VIA EDGAR Tyler Howes Jennifer Gowetski Division of Corporation Finance Disclosure Review Program U.S. Securities and Exchange Commission 100 F Street, N.E. Washington, D.C. 20549 Re: Burning Rock Biotech Limited (the “Company”) Form 20-F for the Year E |
|
| June 28, 2023 |
Burning Rock Announces Resignation and Appointment of Directors EX-99.1 Exhibit 99.1 Burning Rock Announces Resignation and Appointment of Directors GUANGZHOU, China, June 28, 2023 — Burning Rock Biotech Limited (NASDAQ: BNR and LSE: BNR, the “Company” or “Burning Rock”), a company focused on the application of next generation sequencing (NGS) technology in the field of precision oncology, today announced the resignation of Dr. Shaokun (Shannon) Chuai as a dir |
|
| June 28, 2023 |
Form 6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of June 2023 Commission File Number: 001-39316 BURNING ROCK BIOTECH LIMITED (Registrant’s Name) No.5 Xingdao Ring Road North, International Bio Island Guangzhou, Guangdong People’s Republ |
|
| May 30, 2023 |
Burning Rock Reports First Quarter 2023 Financial Results EX-99.1 Exhibit 99.1 Burning Rock Reports First Quarter 2023 Financial Results GUANGZHOU, China, May 30, 2023—Burning Rock Biotech Limited (NASDAQ: BNR and LSE: BNR, the “Company” or “Burning Rock”), a company focused on the application of next generation sequencing (NGS) technology in the field of precision oncology, today reported financial results for the three months ended March 31, 2023. Rece |
|
| May 30, 2023 |
Form 6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of May 2023 Commission File Number: 001-39316 BURNING ROCK BIOTECH LIMITED (Registrant’s Name) No.5 Xingdao Ring Road North, International Bio Island Guangzhou, Guangdong People’s Republi |
|
| April 20, 2023 |
Consent of Ernst & Young Hua Ming LLP, an independent registered public accounting firm Exhibit 15.1 Consent of Independent Registered Public Accounting Firm We consent to the incorporation by reference in the following Registration Statements: (1) Registration Statement (Form S-8 No. 333-251191) pertaining to the Pre-IPO Share Incentive Plan, 2020 Equity Incentive Plan, Management Share Incentive Plan, Employee Share Incentive Plan No.1 and Employee Share Incentive Plan No. 2 of Bur |
|
| April 20, 2023 |
EX-13.1 Exhibit 13.1 CERTIFICATION BY THE PRINCIPAL EXECUTIVE OFFICER PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002 In connection with the Annual Report of Burning Rock Biotech Limited (the “Company”) on Form 20-F for the fiscal year ended December 31, 2022 as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I, Yusheng Han, Chairman of the Board of D |
|
| April 20, 2023 |
EX-2.4 Exhibit 2.4 Description of Rights of Each Class of Securities Registered under Section 12 of the Securities Exchange Act of 1934 American Depositary Shares (“ADSs”), each representing one Class A ordinary share of Burning Rock Biotech Limited (our company) are listed on the Nasdaq Global Market and the shares are registered under Section 12(b) of the Exchange Act. Class A shares represented |
|
| April 20, 2023 |
Form 6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of April 2023 Commission File Number: 001-39316 BURNING ROCK BIOTECH LIMITED (Registrant’s Name) No.5 Xingdao Ring Road North, International Bio Island Guangzhou, Guangdong People’s Repub |
|
| April 20, 2023 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 20-F (Mark One) ☐ REGISTRATION STATEMENT PURSUANT TO SECTION 12(b) OR (g) OF THE SECURITIES ACT OF 1934 OR ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECUR |
|
| April 20, 2023 |
Exhibit 15.2 Suite 509, Tower A, Corporate Square, 35 Financial Street, Xicheng District, Beijing, China Tel: 86 10 5776 3888 Fax: 86 10 5776 3777 Date: April 20, 2023 To: Burning Rock Biotech Limited (the “Company”) No. 5, Xingdao Ring Road North, International Bio Island, Guangzhou, 510005 The People’s Republic of China Dear Sirs/Madams, We hereby consent to the use of our name under the heading |
|
| April 20, 2023 |
EX-12.1 Exhibit 12.1 CERTIFICATION OF PRINCIPAL EXECUTIVE OFFICER PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002 I, Yusheng Han, certify that: 1. I have reviewed this annual report on Form 20-F of Burning Rock Biotech Limited; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements m |
|
| April 20, 2023 |
EX-12.2 Exhibit 12.2 CERTIFICATION OF PRINCIPAL FINANCIAL OFFICER PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002 I, Leo Li, certify that: 1. I have reviewed this annual report on Form 20-F of Burning Rock Biotech Limited; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, |
|
| April 20, 2023 |
EX-13.2 Exhibit 13.2 CERTIFICATION BY THE PRINCIPAL FINANCIAL OFFICER PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002 In connection with the Annual Report of Burning Rock Biotech Limited (the “Company”) on Form 20-F for the fiscal year ended December 31, 2022 as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I, Leo Li, Chief Financial Officer of the |
|
| March 28, 2023 |
Burning Rock Reports Fourth Quarter and Full Year 2022 Financial Results EX-99.1 Exhibit 99.1 Burning Rock Reports Fourth Quarter and Full Year 2022 Financial Results GUANGZHOU, China, March 28, 2023—Burning Rock Biotech Limited (NASDAQ: BNR and LSE: BNR, the “Company” or “Burning Rock”), a company focused on the application of next generation sequencing (NGS) technology in the field of precision oncology, today reported financial results for the three months and the y |
|
| March 28, 2023 |
Form 6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of March 2023 Commission File Number: 001-39316 BURNING ROCK BIOTECH LIMITED (Registrant’s Name) No.5 Xingdao Ring Road North, International Bio Island Guangzhou, Guangdong People’s Repub |
|
| February 13, 2023 |
SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULES 13d-1 (b), (c) AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO 13d-2 (b) (Amendment No. 1)* Burning Rock Biotech Limited (Name of Issuer) American Depositary Shares (ADS), each representing 1 Class A Ordinary Share, par value $0.0002 per Share (Tit |
|
| February 13, 2023 |
Schedule 13G Amendment No. 2 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 2)* Burning Rock Biotech Limited (Name of Issuer) Class A Ordinary Shares, par value US$0.0002 per share (Titles of Class of Securities) G17173 108** (CUSIP Number) December 31, 2022 (Date of Event Which Requires Filing of this S |
|
| February 13, 2023 |
EX-99.1 2 d396374dex991.htm EX-99.1 EXHIBIT 99.1 Joint Filing Agreement In accordance with Rule 13d-1(k) promulgated under the Securities Exchange Act of 1934, as amended, the undersigned hereby agree to the joint filing with all other Reporting Persons (as such term is defined in the Schedule 13G referred to below) on behalf of each of them of a statement on Schedule 13G (including amendments the |
|
| February 10, 2023 |
SC 13G 1 bnr21023.htm KYNAM CAPITAL MANAGEMENT, LP UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 Burning Rock Biotech Limited (Name of Issuer) Class A Ordinary Shares (Title of Class of Securities) 12233L107 (CUSIP Number) December 30, 2022 (Date of Event which Requires Filing of this Statement) Check the appropriate |
|
| February 2, 2023 |
BNR / Burning Rock Biotech Limited / Han Yusheng - SC 13G/A Passive Investment SC 13G/A 1 d429745dsc13ga.htm SC 13G/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1)* Burning Rock Biotech Limited (Name of Issuer) Class A Ordinary Shares, par value US$0.0002 per share (Titles of Class of Securities) G17173 108** (CUSIP Number) December 31, 2022 (Date of Event Which Requires Filing |
|
| February 2, 2023 |
EX-99.1 2 d429745dex991.htm EX-99.1 EXHIBIT 99.1 Joint Filing Agreement In accordance with Rule 13d-1(k) promulgated under the Securities Exchange Act of 1934, as amended, the undersigned hereby agree to the joint filing with all other Reporting Persons (as such term is defined in the Schedule 13G referred to below) on behalf of each of them of a statement on Schedule 13G (including amendments the |
|
| January 18, 2023 |
Burning Rock provides an update on 2022 revenue guidance Exhibit 99.1 Burning Rock provides an update on 2022 revenue guidance GUANGZHOU, China, January 18, 2023—Burning Rock Biotech Limited (NASDAQ: BNR and LSE: BNR, the “Company” or “Burning Rock”), a company focused on the application of next generation sequencing (NGS) technology in the field of precision oncology, today announced that it expects the Company’s full-year revenue growth for 2022 to be |
|
| January 18, 2023 |
6-K 1 d429441d6k.htm FORM 6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of January 2023 Commission File Number: 001-39316 BURNING ROCK BIOTECH LIMITED (Registrant’s Name) No.5 Xingdao Ring Road North, International Bio Island Guangzhou, G |
|
| January 4, 2023 |
EX-99.1 Exhibit 99.1 Burning Rock Received FDA Breakthrough Device Designation for its OverC™ Multi-Cancer Detection Blood Test IRVINE, Calif. Jan.03, 2023 - Burning Rock (NASDAQ/LSE: BNR), a company focused on the application of next generation sequencing (NGS) technology in the field of precision oncology, today announced that its OverC™ Multi-Cancer Detection Blood Test (MCDBT) has been granted |
|
| January 4, 2023 |
Form 6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of January 2023 Commission File Number: 001-39316 BURNING ROCK BIOTECH LIMITED (Registrant’s Name) No.5 Xingdao Ring Road North, International Bio Island Guangzhou, Guangdong People’s Rep |
|
| November 16, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of November 2022 Commission File Number: 001-39316 BURNING ROCK BIOTECH LIMITED (Registrant?s Name) No.5 Xingdao Ring Road North, International Bio Island Guangzhou, Guangdong People?s Republic of |
|
| November 16, 2022 |
Burning Rock Reports Third Quarter 2022 Financial Results Exhibit 99.1 Burning Rock Reports Third Quarter 2022 Financial Results GUANGZHOU, China, November 16, 2022?Burning Rock Biotech Limited (NASDAQ: BNR and LSE: BNR, the ?Company? or ?Burning Rock?), a company focused on the application of next generation sequencing (NGS) technology in the field of precision oncology, today reported financial results for the three months ended September 30, 2022. Rec |
|
| November 7, 2022 |
BURNING ROCK BIOTECH LIMITED INDEX TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS Exhibit 99.2 BURNING ROCK BIOTECH LIMITED INDEX TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS PAGES Condensed Consolidated Balance Sheets as of December 31, 2021 and June 30, 2022 F-2 Condensed Consolidated Statements of Comprehensive Loss for the six months ended June 30, 2021 and 2022 F-5 Condensed Consolidated Statements of Shareholders? Equity for the six months ended June 30, 2021 and 20 |
|
| November 7, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of November 2022 Commission File Number: 001-39316 BURNING ROCK BIOTECH LIMITED (Registrant?s Name) No.5 Xingdao Ring Road North, International Bio Island Guangzhou, Guangdong People?s Republic of |
|
| November 7, 2022 |
Table of Contents Filed pursuant to Rule 424(b)(5) Registration No. 333-264577 PROSPECTUS SUPPLEMENT (To prospectus dated September 30, 2022) Up to $100,000,000 Burning Rock Biotech Limited American Depositary Shares (Representing Class A Ordinary Shares) We have entered into a sales agreement with Cowen and Company, LLC, or Cowen, relating to our American Depositary Shares, or ADSs, representing |
|
| November 7, 2022 |
Exhibit 107.1 The prospectus supplement to which this Exhibit is attached is a final prospectus for the related offering. The maximum aggregate offering price of the offering is $100,000,000. |
|
| November 7, 2022 |
Exhibit 1.1 BURNING ROCK BIOTECH LIMITED $100,000,000 AMERICAN DEPOSITARY SHARES EACH REPRESENTING ONE CLASS A ORDINARY SHARE SALES AGREEMENT November 7, 2022 Cowen and Company, LLC 599 Lexington Avenue New York, NY 10022 Ladies and Gentlemen: Burning Rock Biotech Limited, a Cayman Islands exempted company (the ?Company?), confirms its agreement (this ?Agreement?) with Cowen and Company, LLC (?Cow |
|
| November 7, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of November 2022 Commission File Number: 001-39316 BURNING ROCK BIOTECH LIMITED (Registrant?s Name) No.5 Xingdao Ring Road North, International Bio Island Guangzhou, Guangdong People?s Republic of |
|
| November 7, 2022 |
Exhibit 99.1 Management?s Discussion and Analysis of Financial Condition and Results of Operations Discussion and analysis below are limited to the operations of Burning Rock Biotech Limited (?we? or ?us?). Summary Consolidated Financial and Operating Data The summary unaudited interim consolidated financial information for the six months ended June 30, 2021 and 2022 and as of June 30, 2022 has be |
|
| November 7, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of November 2022 Commission File Number: 001-39316 BURNING ROCK BIOTECH LIMITED (Registrant?s Name) No.5 Xingdao Ring Road North, International Bio Island Guangzhou, Guangdong People?s Republic of |
|
| November 2, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of November 2022 Commission File Number: 001-39316 BURNING ROCK BIOTECH LIMITED (Registrant?s Name) No.5 Xingdao Ring Road North, International Bio Island Guangzhou, Guangdong People?s Republic of |
|
| November 2, 2022 |
Exhibit 99.1 NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR PART, DIRECTLY OR INDIRECTLY, IN OR INTO OR FROM AUSTRALIA, CANADA, SOUTH AFRICA OR JAPAN OR ANY OTHER JURISDICTION WHERE SUCH DISTRIBUTION WOULD BE UNLAWFUL. BURNING ROCK BIOTECH LIMITED ? Admission to Trading on the London Stock Exchange 1 November 2022 Neither this announcement, nor anything contained herein, nor anything co |
|
| October 31, 2022 |
Exhibit (a)(ii) EXECUTION VERSION DEPOSIT AGREEMENT by and among BURNING ROCK BIOTECH LIMITED and CITIBANK, N. |
|
| October 31, 2022 |
Exhibit (a)(i) [FORM OF ADR] Number: CUSIP NUMBER: The American Depositary Shares represented by this American Depositary Receipt are listed on both the Nasdaq Global Market (NASDAQ) and the London Stock Exchange (LSE). |
|
| October 31, 2022 |
Exhibit (e) Rule 466 Certification The depositary, Citibank, N.A., represents and certifies the following: (i) That it had previously filed a registration statement on Form F-6 (Registration No. 333-238921) with respect to Burning Rock Biotech Limited, which the U.S. Securities and Exchange Commission declared effective, with terms of deposit identical to the terms of deposit of this Form F-6 Regi |
|
| October 31, 2022 |
As filed with the Securities and Exchange Commission on October 31, 2022 Registration No. |
|
| October 31, 2022 |
Listing of Burning Rock Biotech Limited ADSs on London Stock Exchange Exhibit (b) Execution Version As of October 31, 2022 Citibank, N.A. ? ADR Depositary 388 Greenwich Street New York, New York 10013 Attn: Account Management Listing of Burning Rock Biotech Limited ADSs on London Stock Exchange Dear Sir/Madam, Reference is hereby made to the Deposit Agreement, dated as of June 16, 2020 and as amended and supplemented (as so amended and supplemented from time to time |
|
| October 27, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of October 2022 Commission File Number: 001-39316 BURNING ROCK BIOTECH LIMITED (Registrant?s Name) No.5 Xingdao Ring Road North, International Bio Island Guangzhou, Guangdong People?s Republic of |
|
| October 27, 2022 |
As at 31 August 2022 ($ thousands) Exhibit 99.1 NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR PART, DIRECTLY OR INDIRECTLY, IN OR INTO OR FROM AUSTRALIA, CANADA, SOUTH AFRICA OR JAPAN OR ANY OTHER JURISDICTION WHERE SUCH DISTRIBUTION WOULD BE UNLAWFUL. BURNING ROCK BIOTECH LIMITED ? Approval and Publication of Prospectus 27 October 2022 This announcement is an advertisement for the purposes of the Prospectus Regulation |
|
| October 21, 2022 |
Exhibit 99.1 NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR PART, DIRECTLY OR INDIRECTLY, IN OR INTO OR FROM AUSTRALIA, CANADA, SOUTH AFRICA OR JAPAN OR ANY OTHER JURISDICTION WHERE SUCH DISTRIBUTION WOULD BE UNLAWFUL. BURNING ROCK BIOTECH LIMITED ? Proposed Direct Listing on the London Stock Exchange and Publication of Registration Document 21 October 2022 Neither this announcement, no |
|
| October 21, 2022 |
6-K 1 d307947d6k.htm FORM 6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of October 2022 Commission File Number: 001-39316 BURNING ROCK BIOTECH LIMITED (Registrant’s Name) No.5 Xingdao Ring Road North, International Bio Island Guangzhou, G |
|
| September 28, 2022 |
Burning Rock Biotech Limited September 28, 2022 VIA EDGAR Christine Westbrook Celeste Murphy Office of Life Sciences Division of Corporation Finance U. |
|
| September 28, 2022 |
As filed with the Securities and Exchange Commission on September 28, 2022 Table of Contents As filed with the Securities and Exchange Commission on September 28, 2022 Registration No. |
|
| September 20, 2022 |
September 20, 2022 Christine Westbrook Celeste Murphy Office of Life Sciences Division of Corporation Finance U. |
|
| September 20, 2022 |
As filed with the Securities and Exchange Commission on September 20, 2022 Table of Contents As filed with the Securities and Exchange Commission on September 20, 2022 Registration No. |
|
| September 12, 2022 |
Hysan Place, 37th Floor 500 Hennessy Road, Causeway Bay Hong Kong T: +852 2521 4122 F: +852 2845 9026 clearygottlieb. |
|
| September 12, 2022 |
As filed with the Securities and Exchange Commission on September 12, 2022 Table of Contents As filed with the Securities and Exchange Commission on September 12, 2022 Registration No. |
|
| September 8, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of September 2022 Commission File Number: 001-39316 BURNING ROCK BIOTECH LIMITED (Registrant?s Name) No.5 Xingdao Ring Road North, International Bio Island Guangzhou, Guangdong People?s Republic o |
|
| September 8, 2022 |
Burning Rock Announces Results of 2022 Annual General Meeting Exhibit 99.1 Burning Rock Announces Results of 2022 Annual General Meeting GUANGZHOU, China, September 8, 2022?Burning Rock Biotech Limited (NASDAQ: BNR, the ?Company? or ?Burning Rock?), a company focusing on the application of next generation sequencing (NGS) technology in the field of precision oncology, today announced that all shareholder resolutions proposed at the Company?s 2022 annual gene |
|
| September 6, 2022 |
Burning Rock Biotech Limited No. 5, Xingdao Ring Road North International Bio Island Guangzhou 510005 People?s Republic of China September 6, 2022 VIA EDGAR Jenn Do Daniel Gordon Division of Corporation Finance Office of Life Sciences U.S. Securities and Exchange Commission 100 F Street, N.E. Washington, D.C. 20549 Re: Burning Rock Biotech Limited (the ?Company?) Form 20-F for the fiscal year ende |
|
| August 31, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of August 2022 Commission File Number: 001-39316 BURNING ROCK BIOTECH LIMITED (Registrant?s Name) No.5 Xingdao Ring Road North, International Bio Island Guangzhou, Guangdong People?s Republic of C |
|
| August 31, 2022 |
Burning Rock Reports Second Quarter 2022 Financial Results Exhibit 99.1 Burning Rock Reports Second Quarter 2022 Financial Results GUANGZHOU, China, August 31, 2022?Burning Rock Biotech Limited (NASDAQ: BNR, the ?Company? or ?Burning Rock?), a company focused on the application of next generation sequencing (NGS) technology in the field of precision oncology, today reported financial results for the three months ended June 30, 2022. Recent Business Update |
|
| August 16, 2022 |
As filed with the Securities and Exchange Commission on August 16, 2022 Table of Contents As filed with the Securities and Exchange Commission on August 16, 2022 Registration No. |
|
| August 16, 2022 |
Hysan Place, 37th Floor 500 Hennessy Road, Causeway Bay Hong Kong T: +852 2521 4122 F: +852 2845 9026 clearygottlieb. |
|
| August 3, 2022 |
Burning Rock Announces 2022 Annual General Meeting to be Held on September 8, 2022 Exhibit 99.1 Burning Rock Announces 2022 Annual General Meeting to be Held on September 8, 2022 GUANGZHOU, China, August 3, 2022—Burning Rock Biotech Limited (NASDAQ: BNR, the “Company” or “Burning Rock”), a company focusing on the application of next generation sequencing (NGS) technology in the field of precision oncology, today announced that it will hold its annual general meeting (“AGM”) on S |
|
| August 3, 2022 |
BURNING ROCK BIOTECH LIMITED NOTICE OF ANNUAL GENERAL MEETING TO BE HELD ON SEPTEMBER 8, 2022 Exhibit 99.2 BURNING ROCK BIOTECH LIMITED NOTICE OF ANNUAL GENERAL MEETING TO BE HELD ON SEPTEMBER 8, 2022 NOTICE IS HEREBY GIVEN that the annual general meeting (the “AGM”) of Burning Rock Biotech Limited (NASDAQ: BNR, the “Company” or “Burning Rock”) will be held on September 8, 2022 at the Company’s Shanghai office at 5/F, Building 1, No. 138 Xinjunhuan Road, Minhang District, Shanghai for the |
|
| August 3, 2022 |
6-K 1 d381334d6k.htm FORM 6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of August 2022 Commission File Number: 001-39316 BURNING ROCK BIOTECH LIMITED (Registrant’s Name) No.5 Xingdao Ring Road North, International Bio Island Guangzhou, Gu |
|
| August 3, 2022 |
Exhibit 99.3 BURNING ROCK BIOTECH LIMITED FORM OF PROXY FOR THE ANNUAL GENERAL MEETING TO BE HELD ON SEPTEMBER 8, 2022 (OR ANY ADJOURNMENTS OR POSTPONEMENTS THEREOF) Introduction This Form of Proxy is furnished in connection with the solicitation by the Board of Directors of Burning Rock Biotech Limited, an exempted company incorporated in the Cayman Islands with limited liability (the “Company”), |
|
| July 15, 2022 |
Burning Rock Announces Resignation of Director Exhibit 99.1 Burning Rock Announces Resignation of Director GUANGZHOU, China, July 15, 2022 ? Burning Rock Biotech Limited (NASDAQ: BNR, the ?Company? or ?Burning Rock?), a company focused on the application of next generation sequencing (NGS) technology in the field of precision oncology, today announced the resignation of Ms. Yunxia Yang as a director from the board of directors of the Company ( |
|
| July 15, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of July 2022 Commission File Number: 001-39316 BURNING ROCK BIOTECH LIMITED (Registrant?s Name) No.5 Xinghuan Ring Road North, International Bio Island Guangzhou, Guangdong People?s Republic of Ch |
|
| June 24, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of June 2022 Commission File Number: 001-39316 BURNING ROCK BIOTECH LIMITED (Registrant?s Name) No.5 Xinghuan Ring Road North, International Bio Island Guangzhou, Guangdong People?s Republic of Ch |
|
| June 24, 2022 |
Burning Rock Announces Changes to Board Composition Exhibit 99.1 Burning Rock Announces Changes to Board Composition GUANGZHOU, China, June 24, 2022 ? Burning Rock Biotech Limited (NASDAQ: BNR, the ?Company? or ?Burning Rock?), a company focused on the application of next generation sequencing (NGS) technology in the field of precision oncology, today announced the resignation of Mr. Jing Rong as a director from the Board, and the appointment of Dr |
|
| June 21, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of June 2022 Commission File Number: 001-39316 BURNING ROCK BIOTECH LIMITED (Registrant?s Name) No.5 Xinghuan Ring Road North, International Bio Island Guangzhou, Guangdong People?s Republic of Ch |
|
| June 21, 2022 |
Burning Rock Announces US$10 Million Share Repurchase Program Exhibit 99.1 Burning Rock Announces US$10 Million Share Repurchase Program GUANGZHOU, China, June 21, 2022 ? Burning Rock Biotech Limited (NASDAQ: BNR, the ?Company? or ?Burning Rock?), a company focused on the application of next generation sequencing (NGS) technology in the field of precision oncology, today announced that its board of directors has authorized a share repurchase plan under which |
|
| June 21, 2022 |
Burning Rock Announces Plan to Pursue An Alternative Listing Exhibit 99.1 Burning Rock Announces Plan to Pursue An Alternative Listing GUANGZHOU, China, June 21, 2022 ? Burning Rock Biotech Limited (NASDAQ: BNR, the ?Company? or ?Burning Rock?), a company focused on the application of next generation sequencing (NGS) technology in the field of precision oncology, today announced that the Board of Directors of the Company (the ?Board?) approved a motion to p |
|
| June 21, 2022 |
As filed with the Securities and Exchange Commission on June 21, 2022 Table of Contents As filed with the Securities and Exchange Commission on June 21, 2022 Registration No. |
|
| June 21, 2022 |
6-K 1 d381696d6k.htm FORM 6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of June 2022 Commission File Number: 001-39316 BURNING ROCK BIOTECH LIMITED (Registrant’s Name) No.5 Xinghuan Ring Road North, International Bio Island Guangzhou, Gua |
|
| June 21, 2022 |
CLEARY GOTTLIEB STEEN & HAMILTON (HONG KONG) CLEARY GOTTLIEB STEEN & HAMILTON (HONG KONG) FREEMAN CHAN SHUANG ZHAO DENISE SHIU PARTNERS CHRIS CHURL-MIN LEE1 REGISTERED FOREIGN LAWYER ROBERT K. |
|
| May 31, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of May 2022 Commission File Number: 001-39316 BURNING ROCK BIOTECH LIMITED (Registrant?s Name) No.5 Xinghuan Ring Road North, International Bio Island Guangzhou, Guangdong People?s Republic of Chi |
|
| May 31, 2022 |
Burning Rock Reports First Quarter 2022 Financial Results Exhibit 99.1 Burning Rock Reports First Quarter 2022 Financial Results GUANGZHOU, China, May 31, 2022 ?Burning Rock Biotech Limited (NASDAQ: BNR, the ?Company? or ?Burning Rock?), a company focused on the application of next generation sequencing (NGS) technology in the field of precision oncology, today reported financial results for the three months ended March 31, 2022. Recent Business Updates |
|
| April 29, 2022 |
EX-13.1 Exhibit 13.1 CERTIFICATION BY THE PRINCIPAL EXECUTIVE OFFICER PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002 In connection with the Annual Report of Burning Rock Biotech Limited (the “Company”) on Form 20-F for the fiscal year ended December 31, 2021 as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I, Yusheng Han, Chairman of the Board of D |
|
| April 29, 2022 |
EX-13.2 Exhibit 13.2 CERTIFICATION BY THE PRINCIPAL FINANCIAL OFFICER PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002 In connection with the Annual Report of Burning Rock Biotech Limited (the “Company”) on Form 20-F for the fiscal year ended December 31, 2021 as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I, Leo Li, Chief Financial Officer of the |
|
| April 29, 2022 |
EX-15.2 8 d238217dex152.htm EX-15.2 Exhibit 15.2 10/F, CPIC Plaza, No. 28 Fengsheng Hutong, Xicheng District, Beijing 100032, China Tel: 86 10 5776 3888 Fax: 86 10 5776 3777 Date: April 29, 2022 To: Burning Rock Biotech Limited (the “Company”) No. 5, Xingdao Ring Road North, International Bio Island, Guangzhou, 510005 The People’s Republic of China Dear Sirs/Madams, We hereby consent to the use of |
|
| April 29, 2022 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 20-F (Mark One) ? REGISTRATION STATEMENT PURSUANT TO SECTION 12(b) OR (g) OF THE SECURITIES ACT OF 1934 OR ? ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2021 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECUR |
|
| April 29, 2022 |
Consent of Ernst & Young Hua Ming LLP, an independent registered public accounting firm EX-15.1 7 d238217dex151.htm EX-15.1 Exhibit 15.1 Consent of Independent Registered Public Accounting Firm We consent to the incorporation by reference in the Registration Statement (Form S-8 No. 333-251191) pertaining to the Pre-IPO Share Incentive Plan, 2020 Equity Incentive Plan, Management Share Incentive Plan, Employee Share Incentive Plan No. 1 and Employee Share Incentive Plan No. 2 of Burni |
|
| April 29, 2022 |
As filed with the Securities and Exchange Commission on April 29, 2022 Table of Contents As filed with the Securities and Exchange Commission on April 29, 2022 Registration No. |
|
| April 29, 2022 |
Exhibit 107 Calculation of Filing Fee Table Form F-3 (Form Type) Burning Rock Biotech Limited (Exact Name of Registrant as Specified in its Charter) Security Type Security Class Title(1) Fee Calculation or Carry Forward Rule Amount Registered Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Carry Forward Form Type Carry Forward File Number Carry Forward Initial effective date Filing Fee Previously Paid In Connection with Unsold Securities to be Carried Forward Newly Registered Securities Fees to be Paid Equity Class A Ordinary Shares(2) Debt Securities Debt Securities Other Warrants Unallocated (Universal) Shelf Unallocated (Universal) Shelf 457(o) (3) (4) US$200,000,000 US$0. |
|
| April 29, 2022 |
EX-12.2 Exhibit 12.2 CERTIFICATION OF PRINCIPAL FINANCIAL OFFICER PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002 I, Leo Li, certify that: 1. I have reviewed this annual report on Form 20-F of Burning Rock Biotech Limited; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, |
|
| April 29, 2022 |
Exhibit 4.4 INDENTURE Dated as of [ ] Between Burning Rock Biotech Limited as the Company and [ ] as the Trustee DEBT SECURITIES BURNING ROCK BIOTECH LIMITED Reconciliation and tie between Trust Indenture Act of 1939 and the Indenture, dated as of , 20[ ]1 Trust Indenture Act Section Indenture Section Sec. 310 (a)(1) 10.04(a) (a)(2) 10.04(a) (a)(3) TIA (a)(4) N.A. (a)(5) TIA (b) 10.04(b); 10.05 Se |
|
| April 29, 2022 |
EX-12.1 Exhibit 12.1 CERTIFICATION OF PRINCIPAL EXECUTIVE OFFICER PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002 I, Yusheng Han, certify that: 1. I have reviewed this annual report on Form 20-F of Burning Rock Biotech Limited; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements m |
|
| March 22, 2022 |
Burning Rock Reports Fourth Quarter and Full Year 2021 Financial Results Exhibit 99.1 Burning Rock Reports Fourth Quarter and Full Year 2021 Financial Results GUANGZHOU, China, March 22, 2022 ?Burning Rock Biotech Limited (NASDAQ: BNR, the ?Company? or ?Burning Rock?), a company focused on the application of next generation sequencing (NGS) technology in the field of precision oncology, today reported financial results for the three months and the year ended December 3 |
|
| March 22, 2022 |
6-K 1 d340508d6k.htm FORM 6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of March 2022 Commission File Number: 001-39316 BURNING ROCK BIOTECH LIMITED (Registrant’s Name) No. 5 Xingdao Ring Road North, International Bio Island Guangzhou, Gu |
|
| February 11, 2022 |
BNR / Burning Rock Biotech Limited / SCC Venture VI Holdco, LTD. - SC 13G/A Passive Investment SC 13G/A SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G (Rule 13d-102) Information to be Included in Statements Filed Pursuant to § 240.13d-1(b), (c) and (d) and Amendments Thereto Filed Pursuant to § 240.13d-2 Under the Securities Exchange Act of 1934 (Amendment No. 1)* Burning Rock Biotech Limited (Name of Issuer) Class A Ordinary Shares, par value $0.0002 per share (Titl |
|
| February 11, 2022 |
EXHIBIT 99.1 Joint Filing Agreement In accordance with Rule 13d-1(k) promulgated under the Securities Exchange Act of 1934, as amended, the undersigned hereby agree to the joint filing with all other Reporting Persons (as such term is defined in the Schedule 13G referred to below) on behalf of each of them of a statement on Schedule 13G (including amendments thereto) with respect to the Class A or |
|
| February 11, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1)* Burning Rock Biotech Limited (Name of Issuer) Class A Ordinary Shares, par value US$0.0002 per share (Titles of Class of Securities) G17173 108** (CUSIP Number) December 31, 2021 (Date of Event Which Requires Filing of this Statement) Check the appropria |
|
| February 10, 2022 |
BNR / Burning Rock Biotech Limited / GIC Private Ltd - SC 13G/A Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1) * Burning Rock Biotech Limited (Name of Issuer) American depositary shares, each representing one Class A ordinary shares, par value US$0.0002 per share (Title of Class of Securities) 12233L107 (CUSIP Number) December 31, 2021 (Date of the Event Which Req |
|
| February 7, 2022 |
SC 13G/A 1 d286762dsc13ga.htm SCHEDULE 13G AMENDMENT NO. 1 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1)* Burning Rock Biotech Limited (Name of Issuer) Class A Ordinary Shares, par value US$0.0002 per share (Titles of Class of Securities) G17173 108** (CUSIP Number) December 31, 2021 (Date of Event W |
|
| February 7, 2022 |
EXHIBIT 99.1 Joint Filing Agreement In accordance with Rule 13d-1(k) promulgated under the Securities Exchange Act of 1934, as amended, the undersigned hereby agree to the joint filing with all other Reporting Persons (as such term is defined in the Schedule 13G referred to below) on behalf of each of them of a statement on Schedule 13G (including amendments thereto) with respect to the Class A or |
|
| February 7, 2022 |
EXHIBIT 99.1 Joint Filing Agreement In accordance with Rule 13d-1(k) promulgated under the Securities Exchange Act of 1934, as amended, the undersigned hereby agree to the joint filing with all other Reporting Persons (as such term is defined in the Schedule 13G referred to below) on behalf of each of them of a statement on Schedule 13G (including amendments thereto) with respect to the Class A or |
|
| February 7, 2022 |
Schedule 13G Amendment No. 1 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 205491 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1)* Burning Rock Biotech Limited (Name of Issuer) Class A Ordinary Shares, par value US$0.0002 per share (Titles of Class of Securities) G17173 108** (CUSIP Number) December 31, 2021 (Date of Event Which Requires Filing of this |
|
| December 29, 2021 |
Burning Rock Announces Results of 2021 Annual General Meeting Exhibit 99.1 Burning Rock Announces Results of 2021 Annual General Meeting GUANGZHOU, China, December 28, 2021?Burning Rock Biotech Limited (NASDAQ: BNR, the ?Company? or ?Burning Rock?), a company focused on the application of next generation sequencing (NGS) technology in the field of precision oncology, today announced that all shareholder resolutions proposed at the Company?s 2021 annual gener |
|
| December 29, 2021 |
Burning Rock Reaffirms 2021 Revenue Guidance of RMB500 Million Exhibit 99.2 Burning Rock Reaffirms 2021 Revenue Guidance of RMB500 Million Guangzhou, China, December 29, 2021 ? Burning Rock Biotech Limited (NASDAQ: BNR, the ?Company? or ?Burning Rock?) today announced that, based on the latest operating trends, the Company expects its 2021 revenue to be at or slightly above RMB500 million. The Company is pleased with the recent progress achieved, despite elev |
|
| December 29, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of December 2021 Commission File Number: 001-39316 BURNING ROCK BIOTECH LIMITED (Registrant?s Name) 601, 6/F, Building 3, Standard Industrial Unit 2 No.7 Luoxuan 4th Road, International Bio Island |
|
| November 16, 2021 |
BURNING ROCK BIOTECH LIMITED NOTICE OF ANNUAL GENERAL MEETING TO BE HELD ON DECEMBER 28, 2021 Exhibit 99.3 BURNING ROCK BIOTECH LIMITED NOTICE OF ANNUAL GENERAL MEETING TO BE HELD ON DECEMBER 28, 2021 NOTICE IS HEREBY GIVEN that the annual general meeting (the ?AGM?) of Burning Rock Biotech Limited (NASDAQ: BNR, the ?Company? or ?Burning Rock?) will be held on December 28, 2021 at the Company?s Shanghai office at 5/F, Building 1, No. 138 Xinjunhuan Road, Minhang District, Shanghai and Clea |
|
| November 16, 2021 |
Burning Rock Reports Third Quarter 2021 Financial Results Exhibit 99.1 Burning Rock Reports Third Quarter 2021 Financial Results GUANGZHOU, China, November 16, 2021?Burning Rock Biotech Limited (NASDAQ: BNR, the ?Company? or ?Burning Rock?), a company focused on the application of next generation sequencing (NGS) technology in the field of precision oncology, today reported financial results for the three months ended September 30, 2021. Business Updates |
|
| November 16, 2021 |
Burning Rock Announces 2021 Annual General Meeting to be Held on December 28, 2021 Exhibit 99.2 Burning Rock Announces 2021 Annual General Meeting to be Held on December 28, 2021 GUANGZHOU, China, November 16, 2021?Burning Rock Biotech Limited (NASDAQ: BNR, the ?Company? or ?Burning Rock?), a company focusing on the application of next generation sequencing (NGS) technology in the field of precision oncology, today announced that it will hold its annual general meeting (?AGM?) o |
|
| November 16, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of November 2021 Commission File Number: 001-39316 BURNING ROCK BIOTECH LIMITED (Registrant?s Name) 601, 6/F, Building 3, Standard Industrial Unit 2 No.7 Luoxuan 4th Road, International Bio Island |
|
| November 16, 2021 |
Exhibit 99.4 BURNING ROCK BIOTECH LIMITED FORM OF PROXY FOR THE ANNUAL GENERAL MEETING TO BE HELD ON DECEMBER 28, 2021 (OR ANY ADJOURNMENTS OR POSTPONEMENTS THEREOF) Introduction This Form of Proxy is furnished in connection with the solicitation by the Board of Directors of Burning Rock Biotech Limited, an exempted company incorporated in the Cayman Islands with limited liability (the ?Company?), |
|
| August 31, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of August 2021 Commission File Number: 001-39316 BURNING ROCK BIOTECH LIMITED (Registrant?s Name) 601, 6/F, Building 3, Standard Industrial Unit 2 No.7 Luoxuan 4th Road, International Bio Island G |
|
| August 31, 2021 |
Burning Rock Reports Second Quarter 2021 Financial Results Exhibit 99.1 Burning Rock Reports Second Quarter 2021 Financial Results GUANGZHOU, China, August 31, 2021?Burning Rock Biotech Limited (NASDAQ: BNR, the ?Company? or ?Burning Rock?), a company focused on the application of next generation sequencing (NGS) technology in the field of precision oncology, today reported financial results for the three months ended June 30, 2021. Business Updates ? Ear |
|
| August 6, 2021 |
BNR / Burning Rock Biotech Limited / GIC Private Ltd - SC 13G Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. ) * Burning Rock Biotech Limited (Name of Issuer) American depositary shares, each representing one Class A ordinary shares, par value US$0.0002 per share (Title of Class of Securities) 12233L107 (CUSIP Number) July 27, 2021 (Date of the Event Which Requires |
|
| May 25, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of May 2021 Commission File Number: 001-39316 BURNING ROCK BIOTECH LIMITED (Registrant?s Name) 601, 6/F, Building 3, Standard Industrial Unit 2 No.7 Luoxuan 4th Road, International Bio Island Guan |
|
| May 25, 2021 |
Burning Rock Reports First Quarter 2021 Financial Results EX-99.1 2 d185453dex991.htm EX-99.1 Exhibit 99.1 Burning Rock Reports First Quarter 2021 Financial Results GUANGZHOU, China, May 25, 2021—Burning Rock Biotech Limited (NASDAQ: BNR, the “Company” or “Burning Rock”), a company focused on the application of next generation sequencing (NGS) technology in the field of precision oncology, today reported financial results for the three months ended March |
|
| March 23, 2021 |
EX-13.1 Exhibit 13.1 CERTIFICATION BY THE PRINCIPAL EXECUTIVE OFFICER PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002 In connection with the Annual Report of Burning Rock Biotech Limited (the “Company”) on Form 20-F for the fiscal year ended December 31, 2020 as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I, Yusheng Han, Chairman of the Board of D |
|
| March 23, 2021 |
EX-13.2 Exhibit 13.2 CERTIFICATION BY THE PRINCIPAL FINANCIAL OFFICER PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002 In connection with the Annual Report of Burning Rock Biotech Limited (the “Company”) on Form 20-F for the fiscal year ended December 31, 2020 as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I, Leo Li, Chief Financial Officer of the |
|
| March 23, 2021 |
Consent of Ernst & Young Hua Ming LLP, an independent registered public accounting firm Exhibit 15.1 Consent of Independent Registered Public Accounting Firm We consent to the incorporation by reference in the Registration Statement (Form S-8 No. 333-251191) pertaining to the Pre-IPO Share Incentive Plan, 2020 Equity Incentive Plan, Management Share Incentive Plan, Employee Share Incentive Plan No.1 and Employee Share Incentive Plan No. 2 of Burning Rock Biotech Limited of our report |
|
| March 23, 2021 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 20-F (Mark One) ? REGISTRATION STATEMENT PURSUANT TO SECTION 12(b) OR (g) OF THE SECURITIES ACT OF 1934 OR ? ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2020 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECUR |
|
| March 23, 2021 |
EX-15.2 9 d24351dex152.htm EX-15.2 Exhibit 15.2 March 23, 2021 To: Burning Rock Biotech Limited (the “Company”) 601, 6/F, Building 3, Standard Industrial Unit 2 No. 7, Luoxuan 4th Road, International Bio Island, Guangzhou, 510005 The People’s Republic of China Ladies and Gentlemen: We hereby consent to the reference of our name under the headings “Item 3. Key Information—D. Risk Factors—Risks Rela |
|
| March 23, 2021 |
EX-12.2 Exhibit 12.2 CERTIFICATION OF PRINCIPAL FINANCIAL OFFICER PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002 I, Leo Li, certify that: 1. I have reviewed this annual report on Form 20-F of Burning Rock Biotech Limited; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, |
|
| March 23, 2021 |
Exhibit 2.4 Description of Rights of Each Class of Securities Registered under Section 12 of the Securities Exchange Act of 1934 American Depositary Shares (?ADSs?), each representing one Class A ordinary share of Burning Rock Biotech Limited (our company) are listed on the Nasdaq Global Market and the shares are registered under Section 12(b) of the Exchange Act. Class A shares represented by the |
|
| March 23, 2021 |
EX-12.1 Exhibit 12.1 CERTIFICATION OF PRINCIPAL EXECUTIVE OFFICER PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002 I, Yusheng Han, certify that: 1. I have reviewed this annual report on Form 20-F of Burning Rock Biotech Limited; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements m |
|
| March 11, 2021 |
Current Report of Foreign Issuer - FORM 6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of March 2021 Commission File Number: 001-39316 BURNING ROCK BIOTECH LIMITED (Registrant?s Name) 601, 6/F, Building 3, Standard Industrial Unit 2 No.7 Luoxuan 4th Road, International Bio Island Gu |
|
| March 11, 2021 |
Burning Rock Reports Fourth Quarter and Full Year 2020 Financial Results EX-99.1 2 d121510dex991.htm EX-99.1 Exhibit 99.1 Burning Rock Reports Fourth Quarter and Full Year 2020 Financial Results GUANGZHOU, China, March 11, 2021—Burning Rock Biotech Limited (NASDAQ: BNR, the “Company” or “Burning Rock”), a company focused on the application of next generation sequencing (NGS) technology in the field of precision oncology, today reported financial results for the three m |
|
| February 12, 2021 |
SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULES 13d-1 (b), (c) AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO 13d-2 (b) (Amendment No. )* Burning Rock Biotech Limited (Name of Issuer) American Depositary Shares (ADS), each representing 1 Class A Ordinary Share, par value $0.0002 per Share (Titl |
|
| February 12, 2021 |
SC 13G SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G (Rule 13d-102) Information to be Included in Statements Filed Pursuant to § 240.13d-1(b), (c) and (d) and Amendments Thereto Filed Pursuant to § 240.13d-2 Under the Securities Exchange Act of 1934 (Amendment No. )* Burning Rock Biotech Limited (Name of Issuer) Class A Ordinary Shares, par value $0.0002 per share (Title o |
|
| February 11, 2021 |
Schedule 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 205491 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* Burning Rock Biotech Limited (Name of Issuer) Class A Ordinary Shares, par value US$0.0002 per share (Titles of Class of Securities) G17173 108** (CUSIP Number) December 31, 2020 (Date of Event Which Requires Filing of this Statement) Check |
|
| February 11, 2021 |
EX-99.1 2 d129428dex991.htm EX-99.1 EXHIBIT 99.1 Joint Filing Agreement In accordance with Rule 13d-1(k) promulgated under the Securities Exchange Act of 1934, as amended, the undersigned hereby agree to the joint filing with all other Reporting Persons (as such term is defined in the Schedule 13G referred to below) on behalf of each of them of a statement on Schedule 13G (including amendments the |
|
| February 11, 2021 |
EX-99.1 EXHIBIT 99.1 Joint Filing Agreement In accordance with Rule 13d-1(k) promulgated under the Securities Exchange Act of 1934, as amended, the undersigned hereby agree to the joint filing with all other Reporting Persons (as such term is defined in the Schedule 13G referred to below) on behalf of each of them of a statement on Schedule 13G (including amendments thereto) with respect to the Cl |
|
| February 11, 2021 |
Schedule 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* Burning Rock Biotech Limited (Name of Issuer) Class A Ordinary Shares, par value US$0.0002 per share (Titles of Class of Securities) G17173 108** (CUSIP Number) December 31, 2020 (Date of Event Which Requires Filing of this Statement) Check t |
|
| February 9, 2021 |
EX-99.1 EXHIBIT 99.1 Joint Filing Agreement In accordance with Rule 13d-1(k) promulgated under the Securities Exchange Act of 1934, as amended, the undersigned hereby agree to the joint filing with all other Reporting Persons (as such term is defined in the Schedule 13G referred to below) on behalf of each of them of a statement on Schedule 13G (including amendments thereto) with respect to the Cl |
|
| February 9, 2021 |
Schedule 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* Burning Rock Biotech Limited (Name of Issuer) Class A Ordinary Shares, par value US$0.0002 per share (Titles of Class of Securities) G17173 108** (CUSIP Number) December 31, 2020 (Date of Event Which Requires Filing of this Statement) Check t |
|
| February 9, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* Burning Rock Biotech Limited (Name of Issuer) Class A Ordinary Shares, par value US$0.0002 per share (Titles of Class of Securities) G17173 108** (CUSIP Number) December 31, 2020 (Date of Event Which Requires Filing of this Statement) Check the appropriat |
|
| February 9, 2021 |
EX-99.1 2 ea134825ex99-1legendbnr.htm JOINT FILING AGREEMENT Exhibit 99.1 Joint Filing Agreement In accordance with Rule 13d-1(k) promulgated under the Securities Exchange Act of 1934, as amended, the undersigned hereby agree to the joint filing with all other Reporting Persons (as such term is defined in the Schedule 13G referred to below) on behalf of each of them of a statement on Schedule 13G |
|
| December 8, 2020 |
English Summary of the Pre-IPO Plan of the Registrant EX-10.1 Exhibit 10.1 English Summary of Pre-IPO Share Incentive Plan of Burning Rock Biotech Limited 1. Definition. Wherever the following terms are used in the Plan they shall have the meanings specified below, unless the context clearly indicates otherwise. a. “Company” means Burning Rock Biotech Limited, a company incorporated under the laws of the Cayman Islands. b. “Option” means a right gran |
|
| December 8, 2020 |
English Summary of the Employee ESIP No. 2 of the Registrant EX-10.5 Exhibit 10.5 English Summary of Employee Share Incentive Plan No.2 of Burning Rock Biotech Limited 1. Definition. Wherever the following terms are used in the Plan they shall have the meanings specified below, unless the context clearly indicates otherwise. a. “Company” means Burning Rock Biotech Limited, a company incorporated under the laws of the Cayman Islands. b. “Participant” means a |
|
| December 8, 2020 |
Form S-8 As filed with the Securities and Exchange Commission on December 8, 2020 Registration No. |
|
| December 8, 2020 |
English Summary of the Employee ESIP No. 1 of the Registrant EX-10.4 Exhibit 10.4 English Summary of Employee Share Incentive Plan No.1 of Burning Rock Biotech Limited 1. Definition. Wherever the following terms are used in the Plan they shall have the meanings specified below, unless the context clearly indicates otherwise. a. “Company” means Burning Rock Biotech Limited, a company incorporated under the laws of the Cayman Islands. b. “Participant” means a |
|
| December 8, 2020 |
English Summary of the Management Plan of the Registrant EX-10.3 Exhibit 10.3 English Summary of Management Share Incentive Plan of Burning Rock Biotech Limited 1. Definition. Wherever the following terms are used in the Plan they shall have the meanings specified below, unless the context clearly indicates otherwise. a. “Company” means Burning Rock Biotech Limited, a company incorporated under the laws of the Cayman Islands. b. “Option” means a right g |
|
| December 4, 2020 |
F-1MEF As filed with the Securities and Exchange Commission on December 3, 2020 Registration No. |
|
| December 4, 2020 |
424(B)(4) Table of Contents Filed Pursuant to Rule 424(b)(4) Registration No. 333-251053 2,243,000 American Depositary Shares Burning Rock Biotech Limited Representing 2,243,000 Class A Ordinary Shares This is a public offering of American depositary shares, or ADSs, representing Class A ordinary shares of Burning Rock Biotech Limited. We are not selling any ADSs. The selling shareholders identifi |
|
| December 2, 2020 |
Burning Rock Announces Proposed Registered Secondary Public Offering of American Depositary Shares EX-99.1 2 d66747dex991.htm EX-99.1 Exhibit 99.1 Burning Rock Announces Proposed Registered Secondary Public Offering of American Depositary Shares GUANGZHOU, China, December 2, 2020 – Burning Rock Biotech Limited (NASDAQ: BNR, the “Company” or “Burning Rock”), a company focused on the application of next generation sequencing (NGS) technology in the field of precision oncology, today announced tha |
|
| December 2, 2020 |
Morgan Stanley & Co. LLC 1585 Broadway New York, New York 10036 United States of America BofA Securities, Inc. One Bryant Park New York, NY 10036 United States of America Cowen and Company, LLC 599 Lexington Avenue New York, NY 10022 United States of America As representatives of the prospective underwriters VIA EDGAR December 2, 2020 Office of Life Sciences Division of Corporation Finance U.S. Se |
|
| December 2, 2020 |
Current Report of Foreign Issuer - FORM 6-K Form 6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of December, 2020 Commission File Number: 001-39316 BURNING ROCK BIOTECH LIMITED (Registrant’s Name) 601, 6/F, Building 3, Standard Industrial Unit 2 No.7 Luoxuan 4th Road, International |
|
| December 2, 2020 |
Burning Rock Biotech Limited December 2, 2020 VIA EDGAR Margaret Schwartz Office of Life Sciences Division of Corporation Finance U. |
|
| December 2, 2020 |
Amendment No.1 to Form F-1 Table of Contents As filed with the Securities and Exchange Commission on December 2, 2020 Registration No. 333-251053 SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 AMENDMENT NO. 1 TO FORM F-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 Burning Rock Biotech Limited (Exact name of Registrant as specified in its charter) Not Applicable (Translation |
|
| December 1, 2020 |
Principal Subsidiaries of the Registrant EX-21.1 Exhibit 21.1 List of Principal Subsidiaries of the Registrant Subsidiaries Place of Incorporation BR Hong Kong Limited Hong Kong Beijing Burning Rock Biotech Limited China Burning Rock Biotechnology (Shanghai) Co., Ltd. China VIE Place of Incorporation Burning Rock (Beijing) Biotechnology Co., Ltd. China Subsidiaries of the VIE Place of Incorporation Guangzhou Burning Rock Biotechnology Co |
|
| December 1, 2020 |
Form of Underwriting Agreement EX-1.1 Exhibit 1.1 [ ] American Depositary Shares BURNING ROCK BIOTECH LIMITED EACH REPRESENTING ONE CLASS A ORDINARY SHARE, PAR VALUE US$0.0002 PER SHARE UNDERWRITING AGREEMENT [ ], 2020 [ ], 2020 Morgan Stanley & Co. LLC 1585 Broadway New York, New York 10036 United States of America BofA Securities, Inc. One Bryant Park New York, NY 10036 United States of America Cowen and Company, LLC 599 Lexi |
|
| December 1, 2020 |
Consent of China Insights Consultancy EX-99.3 7 d88257dex993.htm EX-99.3 Exhibit 99.3 November 12, 2020 Burning Rock Biotech Limited 601, 6/F, Building 3, Standard Industrial Unit 2 No. 7, Luoxuan 4th Road, International Bio Island, Guangzhou, 510005 People’s Republic of China R e: Consent of China Insights Consultancy Ladies and Gentlemen, We, China Insights Consultancy, understand that Burning Rock Biotech Limited (the “Company”) pl |
|
| December 1, 2020 |
Form F-1 Table of Contents As filed with the Securities and Exchange Commission on December 1, 2020 Registration No. |
|
| December 1, 2020 |
Opinion of Shihui Partners regarding certain PRC tax matters (included in Exhibit 99.2) EX-99.2 Exhibit 99.2 December 1, 2020 To: Burning Rock Biotech Limited 601, 6/F, Building 3, Standard Industrial Unit 2 No. 7, Luoxuan 4th Road, International Bio Island, Guangzhou, 510005 People’s Republic of China Dear Sirs or Madams, We are qualified lawyers of the People’s Republic of China (the “PRC” or “China”, for the purpose of this opinion only, the PRC shall not include the Hong Kong Spe |
|
| December 1, 2020 |
Morgan Stanley & Co. LLC 1585 Broadway New York, New York 10036 United States of America BofA Securities, Inc. One Bryant Park New York, NY 10036 United States of America Cowen and Company, LLC 599 Lexington Avenue New York, NY 10022 United States of America As representatives of the prospective underwriters VIA EDGAR December 1, 2020 Office of Life Sciences Division of Corporation Finance U.S. Se |
|
| December 1, 2020 |
Burning Rock Biotech Limited December 1, 2020 VIA EDGAR Margaret Schwartz Office of Life Sciences Division of Corporation Finance U. |
|
| November 20, 2020 |
Burning Rock Reports Third Quarter 2020 Financial Results EX-99.1 Exhibit 99.1 Burning Rock Reports Third Quarter 2020 Financial Results GUANGZHOU, China, November 20, 2020—Burning Rock Biotech Limited (NASDAQ: BNR, the “Company” or “Burning Rock”), a company focused on the application of next generation sequencing (NGS) technology in the field of precision oncology, today reported financial results for the three months ended September 30, 2020. Recent B |
|
| November 20, 2020 |
Current Report of Foreign Issuer - FORM 6-K Form 6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of November, 2020 Commission File Number: 001-39316 BURNING ROCK BIOTECH LIMITED (Registrant’s Name) 601, 6/F, Building 3, Standard Industrial Unit 2 No.7 Luoxuan 4th Road, International |
|
| November 13, 2020 |
Exhibit 21.1 List of Principal Subsidiaries of the Registrant Subsidiaries Place of Incorporation BR Hong Kong Limited Hong Kong Beijing Burning Rock Biotech Limited China Burning Rock Biotechnology (Shanghai) Co., Ltd. China VIE Place of Incorporation Burning Rock (Beijing) Biotechnology Co., Ltd. China Subsidiaries of the VIE Place of Incorporation Guangzhou Burning Rock Biotechnology Co., Ltd. |
|
| November 13, 2020 |
Exhibit 99.3 November 12, 2020 Burning Rock Biotech Limited 601, 6/F, Building 3, Standard Industrial Unit 2 No. 7, Luoxuan 4th Road, International Bio Island, Guangzhou, 510005 People?s Republic of China R e: Consent of China Insights Consultancy Ladies and Gentlemen, We, China Insights Consultancy, understand that Burning Rock Biotech Limited (the ?Company?) plans to file a registration statemen |
|
| November 13, 2020 |
Exhibit 99.2 , 2020 To: Burning Rock Biotech Limited 601, 6/F, Building 3, Standard Industrial Unit 2 No. 7, Luoxuan 4th Road, International Bio Island, Guangzhou, 510005 People?s Republic of China Dear Sirs or Madams, We are qualified lawyers of the People?s Republic of China (the ?PRC? or ?China?, for the purpose of this opinion only, the PRC shall not include the Hong Kong Special Administrativ |
|
| November 13, 2020 |
DRSLTR CLEARY GOTTLIEB STEEN & HAMILTON LLP WASHINGTON, D.C. PARIS BRUSSELS LONDON FRANKFURT COLOGNE MOSCOW One Liberty Plaza New York, NY 10006-1470 T: +1 212 225 2000 F: +1 212 225 3999 Clearygottlieb.com D: +852 2532 3783 [email protected] ROME MILAN HONG KONG BEIJING BUENOS AIRES SÃO PAULO ABU DHABI SEOUL November 13, 2020 CONFIDENTIAL AND VIA EDGAR Draft Registration Statement Securities and Exc |
|
| November 13, 2020 |
Table of Contents As confidentially submitted to the Securities and Exchange Commission on November 13, 2020 Registration No. |
|
| August 11, 2020 |
Current Report of Foreign Issuer - FORM 6-K Form 6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of August, 2020 Commission File Number: 001-39316 BURNING ROCK BIOTECH LIMITED (Registrant’s Name) 601, 6/F, Building 3, Standard Industrial Unit 2 No.7 Luoxuan 4th Road, International Bi |
|
| August 11, 2020 |
Burning Rock Reports Second Quarter 2020 Financial Results EX-99.1 2 d79873dex991.htm EX-99.1 Exhibit 99.1 Burning Rock Reports Second Quarter 2020 Financial Results GUANGZHOU, China, August 11, 2020—Burning Rock Biotech Limited (NASDAQ: BNR, the “Company” or “Burning Rock”), a company focused on the application of next generation sequencing (NGS) technology in the field of precision oncology, today reported financial results for the three months ended Ju |
|
| June 12, 2020 |
424(B)(4) Table of Contents Filed Pursuant to Rule 424(b)(4) Registration No. 333-238596 13,500,000 American Depositary Shares Burning Rock Biotech Limited Representing 13,500,000 Class A Ordinary Shares This is an initial public offering of American depositary shares, or ADSs, representing Class A ordinary shares of Burning Rock Biotech Limited. We are offering 13,500,000 ADSs. Each ADS represent |
|
| June 10, 2020 |
Burning Rock Biotech Limited June 10, 2020 VIA EDGAR Tara Harkins Kevin Kuhar Jeffrey Gabor Christine Westbrook Office of Life Sciences Division of Corporation Finance U. |
|
| June 10, 2020 |
Correspondence Morgan Stanley & Co. LLC 1585 Broadway New York, New York 10036 United States of America BofA Securities, Inc. One Bryant Park New York, NY 10036 United States of America Cowen and Company, LLC 599 Lexington Avenue New York, NY 10022 United States of America As representatives of the prospective underwriters VIA EDGAR June 10, 2020 Securities and Exchange Commission Division of Corp |
|
| June 8, 2020 |
FREE WRITING PROSPECTUS Issuer Free Writing Prospectus Filed Pursuant to Rule 433 Registration No. |
|
| June 8, 2020 |
Amendment No.2 to Form F-1 Table of Contents As filed with the Securities and Exchange Commission on June 8, 2020 Registration No. 333-238596 SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 AMENDMENT NO. 2 TO FORM F-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 Burning Rock Biotech Limited (Exact name of Registrant as specified in its charter) Not Applicable (Translation of R |
|
| June 5, 2020 |
EX-4.3 Exhibit 4.3 DEPOSIT AGREEMENT by and among BURNING ROCK BIOTECH LIMITED and CITIBANK, N.A., as Depositary, and ALL HOLDERS AND BENEFICIAL OWNERS OF AMERICAN DEPOSITARY SHARES ISSUED HEREUNDER Dated as of [date], 2020 TABLE OF CONTENTS ARTICLE I DEFINITIONS 1 Section 1.1 “ADS Record Date” 1 Section 1.2 “Affiliate” 1 Section 1.3 “American Depositary Receipt(s)”, “ADR(s)” and “Receipt(s)” 1 Se |
|
| June 5, 2020 |
Form 8-A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-A FOR REGISTRATION OF CERTAIN CLASSES OF SECURITIES PURSUANT TO SECTION 12(b) OR (g) OF THE SECURITIES EXCHANGE ACT OF 1934 Burning Rock Biotech Limited (Exact name of registrant as specified in its charter) Cayman Islands Not Applicable (State of incorporation or organization) (I.R.S. Employer Identification N |
|
| June 5, 2020 |
EX-3.2 Exhibit 3.2 THE COMPANIES LAW (2020 REVISION) OF THE CAYMAN ISLANDS COMPANY LIMITED BY SHARES TENTH AMENDED AND RESTATED MEMORANDUM OF ASSOCIATION OF BURNING ROCK BIOTECH LIMITED (Adopted by Special Resolution passed on June 3, 2020 and effective immediately prior to the completion of the initial public offering of the Company’s American Depositary Shares representing its Class A Ordinary S |
|
| June 5, 2020 |
EX-99.4 Exhibit 99.4 Burning Rock Biotech Limited 601, 6/F, Building 3, Standard Industrial Unit 2 No. 7, Luoxuan 4th Road International Bio Island Guangzhou, 510005 People’s Republic of China April 16, 2020 Ladies and Gentlemen: Pursuant to Rule 438 promulgated under the Securities Act of 1933, as amended, I hereby consent to be named in the Registration Statement on Form F-1 (the “Registration S |
|
| June 5, 2020 |
CLEARY GOTTLIEB STEEN & HAMILTON LLP WASHINGTON, D.C. PARIS BRUSSELS LONDON FRANKFURT COLOGNE MOSCOW One Liberty Plaza New York, NY 10006-1470 T: +1 212 225 2000 F: +1 212 225 3999 clearygottlieb.com D: +852 2532 3783 [email protected] ROME MILAN HONG KONG BEIJING BUENOS AIRES S?O PAULO ABU DHABI SEOUL June 5, 2020 VIA EDGAR AND OVERNIGHT COURIER Tara Harkins Kevin Kuhar Jeffrey Gabor Christine Westb |
|
| June 5, 2020 |
EX-10.13 Exhibit 10.13 SUBSCRIPTION AGREEMENT THIS SUBSCRIPTION AGREEMENT (this “Agreement”), dated as of June 5, 2020, is entered into by and between: (1) Burning Rock Biotech Limited, a company incorporated in the Cayman Islands (the “Company”); and (2) LAKE BLEU PRIME HEALTHCARE MASTER FUND LIMITED, a company incorporated in the Cayman Islands (the “Purchaser”). The Purchaser and the Company ar |
